- SOPH reported an earnings per share (EPS) of -$0.28 for Q4 2025, missing the estimated EPS but showcasing a 22% year-over-year revenue increase.
- The company’s gross margin improved, with a reported 67.7% and an adjusted 73.9%, indicating the scalability of their AI-native precision medicine platform, SOPHiA DDMTM.
- Despite revenue growth, SOPH experienced a 27% increase in IFRS net loss to $19.2 million and a 9% rise in adjusted EBITDA loss to $9.9 million for Q4 2025.
SOPHiA GENETICS SA, trading on the NASDAQ:SOPH, is a prominent player in AI-driven precision medicine. The company focuses on leveraging artificial intelligence to enhance healthcare outcomes. Despite its innovative approach, SOPH faces financial challenges, as reflected in its recent earnings report for Q4 2025. The earnings call, as highlighted by Seeking Alpha, provided valuable insights into the company’s performance and future plans.
On March 3, 2026, SOPH reported an earnings per share (EPS) of -$0.28, falling short of the estimated EPS of -$0.25. This indicates that the company is currently experiencing losses, as evidenced by its negative price-to-earnings (P/E) ratio of approximately -3.90. However, the company’s revenue for the quarter was $21.7 million, surpassing the estimated $20.7 million, showcasing a 22% year-over-year increase.
SOPH’s gross margin for Q4 2025 was 67.7% on a reported basis and 73.9% on an adjusted basis. This reflects the scalability of their AI-native precision medicine platform, SOPHiA DDMTM, which contributed to a 140 basis point expansion in adjusted gross margin. Despite these gains, the IFRS net loss increased by 27% to $19.2 million, and the adjusted EBITDA loss rose by 9% to $9.9 million.
For the full year 2025, SOPH achieved a revenue of $77.3 million, marking a 19% increase from the previous year. The gross margin remained stable at 67.4% on a reported basis and improved to 74.2% on an adjusted basis. However, the IFRS net loss for the year was $79 million, a 26% increase year-over-year, and the adjusted EBITDA loss was $41.5 million, up by 3%.
SOPH’s financial metrics reveal a mixed picture. The price-to-sales ratio stands at about 3.99, indicating that investors are willing to pay nearly four times the company’s sales per share. The enterprise value to sales ratio is approximately 3.74, reflecting the company’s valuation relative to its sales. However, the enterprise value to operating cash flow ratio is negative at around -7.15, highlighting challenges in generating positive cash flow from operations. Despite these challenges, SOPH maintains a strong current ratio of approximately 2.80, suggesting a solid ability to cover short-term liabilities with short-term assets.
